TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pancreatic metastatic cancer~* Patient older than 18 years~* Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel.~* At least one measurable target lesion~* Patient signed consent for Energie-Pancreas study participation~Exclusion Criteria:~* Other concomitant cancer~* Major general status alteration ( Performance status = 3 or 4 at inclusion)~* Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (\< 1 month), ongoing Healing, hyperthyroidism.~* Smoker~* Patient deprived of his liberty, under guardianship, curator.~* Pregnant patient or breastfeeding~* Claustrophobic patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- energetic expenditure measure (Type: OTHER): To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Signature Personalised Patient Care System With the Vanguard Knee System Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more of the knee compartments are involved~* correction of varus, valgus or posttraumatic deformity~* correction or revision of unsuccessful osteotomy (wedge cut from bone to improve alignment), or arthrodesis (fusion)~* need to obtain pain relief and improve function~* ability and willingness to follow instructions, including control of weight and activity level.~* a good nutritional state~* must have reached full skeletal maturity~* able and willing to undergo an MRI scan~Exclusion Criteria:~* infection~* sepsis~* osteomyelitis~* failure of a previous joint replacement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Signature Knee Guide (Type: EXPERIMENTAL): Vanguard Knee System with Signature Knee Guide
- Conventional Approach (Type: ACTIVE_COMPARATOR): Vanguard Complete Knee System with Conventional Approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven inoperable locally advanced or metastatic adenocarcinoma of the stomach (including adenocarcinoma of the gastrooesophageal junction)~* Patient's age between 20 and 70 years old~* Measurable disease defined by RECIST criteria~* Patients with non-measurable disease could be enrolled in the phase I part of the study~* ECOG performance status ≤ 1~* Hgb ≥ 8g/dL, WBC ≥ 3 x 109/L , neutrophils count ≥ 1.5 x 109/L , platelets ≥100 x 109/L, Creatinine clearance ≥50 mL/min, Total bilirubin ≤ 1.5 X UNL, AST, ALT and ALP ≤ 2.5 x UNL~* No prior chemotherapy or more than 6 months from adjuvant chemotherapy or chemo-radiation~* Estimated life expectancy more than 3 months~* Written informed consent~Exclusion Criteria:~* Gastrointestinal bleeding~* Clinically relevant, symptomatic excessive amounts of ascites resulting in patient's discomfort~* CNS metastases~* History of hypersensitivity to fluoropyrimidines, docetaxel or platinum compounds~* Any previous chemotherapy or radiotherapy for advanced disease~* Patient pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment~* Patient (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment~* Known hypersensitivity reaction to the component of the treatment~* Active infection or malnutrition or bowel obstruction~* Legal incapacity or limited legal capacity~* Definite contraindications for the use of corticosteroids~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan~* Chronic inflammation of the bowel~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment~* Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent~* A second primary tumor other than non-melanoma skin cancer or in situ cervical cancer

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Panitumumab plus DCF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
All candidates must have previously untreated hypertension. The candidates will be picked from patients with stage-1 hypertension (systolic BP 140-159 mm Hg or diastolic BP 90-99 mm Hg) and those with stage-2 hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100), based on the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines (JNC-7).~Inclusion Criteria:~* Presence of inappropriate LVM.~* Presence of phenotype of inappropriate LVM.~Exclusion Criteria:~The criteria will assure that only patients with hypertension are enrolled, that is, excluded will be subjects with systolic BP \< 140 or diastolic BP \< 90 (ie, prehypertension or normal BP), but without complications or any indication (or suspicion) of end-organ damage based on a physical exam, clinical history, or laboratory tests.~Specific exclusion criteria are:~* Reactive airways disease including asthma.~* Diabetes mellitus or hypoglycemia; thyrotoxicosis.~* LV dysfunction (ejection fraction \< 50%) or heart failure.~* Present or previously documented coronary heart disease or angina.~* Acute myocardial infarction, or history of myocardial infarction.~* Severe bradycardia, heart block greater than first degree or sick sinus syndrome (unless a permanent pacemaker is in place).~* Hepatic insufficiency or history of cirrhosis.~* Chronic renal failure or renovascular dysfunction.~* Cerebrovascular dysfunction.~* Peripheral vascular disease.~* Pregnant or nursing women; women of childbearing age will be required to take a pregnancy test at the time of enrollment and use an acceptable method of birth control.~* Poor echo image quality.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: EXPERIMENTAL): Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
- Metoprolol succinate (Type: OTHER): Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3).~* No prior therapy or inadequate response to therapy for hepatitis C.~* Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.~Exclusion Criteria:~* Use of other investigational drugs within at least 30 days of enrollment~* Women of child-bearing potential.~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LCQ908 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinically definite Multiple sclerosis patients (at least 2 relapses)~* Patient having presented another neurological episode suggestive of MULTIPLE SCLEROSIS confirmed or not by a neurologist and allowing to establish the diagnosis of MULTIPLE SCLEROSIS according to the criteria of Mc Donald~* Age ≥ 18 years~* Patients informed about the objectives of the study and about its practical realization~Exclusion Criteria:~* Patient having received a treatment by corticoids in 30 days before the lumbar puncture~* Contraindication of the lumbar puncture such as an anticoagulating oral treatment for example~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Single Time-Point Study to Evaluate the ConforMIS iTotal (PS) Knee Replacement System Versus Off-the-Shelf

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Implant must be a minimum of 6 months post-op and doing well in the opinion of site staff~* Subject has had a knee replacement utilizing a fixed bearing PS (Posterior Stabilized) implant design~* \> 18 years of age~* Willingness to participate in the clinical study, to give informed consent, and to perform all evaluations~Exclusion Criteria:~* Simultaneous or staged bilateral procedure~* BMI \> 40~* Other physical disability that requires an aid for walking or disability affecting the hips, spine, contralateral knee or other joint that limits function~* Participation in another clinical study which would confound results~* Inability to complete the protocol in the opinion of the clinical staff due to safety or other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iTotal PS KRS (Type: None): Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
- Off-the-Shelf KRS (Type: None): Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of non-Hodgkin's lymphoma~* Disease exclusively localised into the CNS at first diagnosis and failure~* Progressive or recurrent disease~* Previous treatment with HDMTX containing CHT and/or RT~* Presence of at least one target lesion, bidimensionally measurable~* Age 18 - 75 years~* ECOG performance status \< 3 (Appendix 1).~* No known HIV disease or immunodeficiency~* HBsAg-negative and Ab anti-HCV-negative patients.~* Adequate bone marrow function (plt \> 100000 mm3, Hb \> 9 g/dl, ANC \> 2.000 mm3)~* Adequate renal function (serum creatinine \< 2 times UNL)~* Adequate hepatic function (SGOT/SGPT \< 3 times UNL, bilirubin and alkaline phosphatase \< 2 times UNL)~* Adequate cardiac function (VEF ≥ 50%)~* Absence of any psycological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule~* Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential.~* No previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in-site of the cervix and basal or squamous cell carcinoma of the skin and of other neoplasms without evidence of disease since at least 5 years.~* No concurrent treatment with other experimental drugs.~* Informed consent signed by the patient before registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feeding After Neonate Surgery Review

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Neonates who undergo cardiac surgery~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* World Health Organization performance index lower or equal to 3~* Estimated life expectancy greater than 3 months~* patient in whom the diagnosis of glioblastoma was histologically proven~* Patient with tumor progression of morphological magnetic resonance imagery evidenced by Pluri Disciplinary Meeting. This increase must meet the detailed criteria Response Assessment Neuro Oncology Working group : except in the case of a new lesion appearing outside of the field of radiotherapy, tumor progression can not therefore be defined on an magnetic resonance imagery performed in a period shorter than 12 weeks after the last day of radiotherapy (see criteria Response Assessment Neuro Oncology Working Group detailed chapter 2-1 B)~* Patient with unilateral tensor above injury at baseline (in order to have in each case a tumor region of interest area and an area equivalent region of interest contralateral healthy tissue) .~* Patient with measurable lesion at baseline, according to the criteria defined by the working group Respons Assessment Neuro Oncology. The lesion with contrast is measured two-dimensionally on T1 gadolinium in axial section. The two perpendicular diameters of red lead should be 10 mm and that at least two axial sections.~* Patient with progression after radiotherapy and have received at least one chemotherapy regimen (temodal)~* A patient in whom treatment with bevacizumab monotherapy~Exclusion Criteria:~* Pregnancy~* Exclusion criteria related to cons to the realization of positron emission tomography or magnetic resonance imagery : Weight greater than 120 kg, Foreign body incompatible with magnetic resonance imagery (eg metallic intraocular foreign body), Medical equipment installed incompatible with magnetic resonance imagery (eg pacemaker)~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with glioblastoma (Type: EXPERIMENTAL): Patient with histologically proved glioblastoma diagnostic will receive the following interventions :~* Cerebral magnetic resonance imagery~* Tomography emission positron with F-MISO~* Bevacizumab administration~* Clinical examination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent must be obtained from the subject or health care proxy before any assessment is performed.~* Adults (male and female) aged 65 years and over.~* Residing in a nursing home in which one or more residents or staff has developed laboratory-confirmed symptomatic COVID-19 infection at the time of randomization~Exclusion Criteria:~Subjects will not be eligible if they meet any of the following criteria:~* Any subject who is a current smoker or has a ≥ 10 pack year smoking history.~* Subjects with a medical history of chronic obstructive pulmonary disease (COPD).~* Subjects who are in hospice or receiving comfort care only.~* Subjects who have symptomatic laboratory-confirmed COVID-19 at the time of screening or randomization.~* Subjects with current evidence of an unstable medical disorder including an unstable respiratory disorder, gastrointestinal disorder (including Child-Pugh class B and C hepatic impairment), renal disorder (including subjects with an estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m2), or hematologic disorder (including active leukemia).~* Subjects receiving immunosuppressive therapy including chronic use of prednisone \>10 mg daily (however, inhaled corticosteroids and acute use of higher doses of prednisone to treat conditions such as exacerbation of asthma or other acute conditions are allowed).~* Subjects with an immunodeficiency disease, including a positive human immunodeficiency virus (HIV) test result.~* Sexually active males with a partner of child-bearing potential

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg daily RTB101 (Type: EXPERIMENTAL): TORC1 inhibitor
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Febrile for at least 36 hours with clinical characteristics of dengue~* Presents for care at the hospital during time of study~* Over the age of 2 years old~* Adults are able and willing to consent or a parent/guardian is willing and able to accept consent for a child.~Exclusion Criteria:~* Adults that are not able to consent~* Minors without parent/guardian consent~* Pregnant women~* Prisoners

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Morbidly obese patients who fulfill the NIH criteria for surgical intervention.~Exclusion Criteria:~* Patients deemed unfit for surgery~* Pregnant women, or who are attempting conception.~* Subjects with any history of myocardial infarction, coronary artery bypass grafting surgery, coronary angiography with angioplasty and/or stenting, or any lesion \> 50% of the coronary artery luminal diameter, cerebrovascular accident, or peripheral vascular disease with abnormal electrocardiograms and/or echocardiography.~* History of drug or alcohol abuse.~* Chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues